ITI is a program of The Task Force for Global Health.
Trachoma prevalence surveys in Pakistan were first conducted in 2007 following Trachoma Rapid Assessments (TRAs) and pilot implementation of SAFE in two districts in 2005. Between 2007 and 2013, a total of 39 districts were surveyed for trachoma prevalence, with two districts identified with active trachoma prevalence over 5%. The national program requested Zithromax® for trachoma MDAs in these two districts for the 2016 program year in their first application to ITI in June 2015. Both districts were approved at the 12th meeting of the Trachoma Expert Committee (TEC 12), contingent on funding for full SAFE implementation.
In 2015, fifteen districts were mapped for trachoma prevalence using the Global Trachoma Mapping Project (GTMP) platform. Six sub-districts were found to have active trachoma prevalence over 5%, with one sub-district over 10% and five, between 5-9.9%. Following recommendations from the TEC, prevalence surveys were conducted at the tehsil or sub-district level.
The national program conducted a two-day Trachoma Action Plan (TAP) workshop in March 2016 with a follow-up workshop scheduled for August 2017.
The Fred Hollows Foundation, Sightsavers and CBM are some of the NGOs that have been active in supporting eye health services in Pakistan.
CURRENT IMPLEMENTATION STATUS
2017 was the first year of trachoma MDAs and full SAFE implementation in Chitral and Shahdadkot districts in KPK and Sindh provinces, respectively. In 2018, the program will scale-up MDAs and SAFE implementation in all endemic districts.
Zithromax® Shipments by Year